1 completed, 1 terminated, 1 unknown, 1 withdrawn. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Gaucher Disease, Type 3: new trials by email Literature Review of Gaucher Disease, Type 3 trials Research Report on Gaucher Disease, Type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3 | Phase 2 / Phase 3 | Withdrawn | AVROBIO | 2023-10-01 | 2023-08-09 | |
| Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease Low-dose CAN103, High-dose CAN103 - Gaucher Disease, Type 1, Gaucher Disease, Type 3 | Phase 1 / Phase 2 | Unknown | CANbridge (Suzhou) Bio-pharma Co., Ltd. | 40 | 2022-07-11 | 2022-07-27 |
| Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 Arimoclomol, Placebo oral capsule - Gaucher Disease, Type 1, Gaucher Disease, Type 3 | Phase 2 | Terminated | ZevraDenmark | 39 | 2018-06-06 | 2023-01-11 |
| Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease velaglucerase alfa - Gaucher Disease, Type 3 | Phase 1 / Phase 2 | Completed | Shire | 7 | 2012-09-14 | 2021-06-11 |
Gaucher Disease (4)
Brain Diseases (4) · Brain Diseases, Metabolic (4) · Brain Diseases, Metabolic, Inborn (4) · Central Nervous System Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Lipid Metabolism Disorders (4) · Lipid Metabolism, Inborn Errors (4) · Lipidoses (4) · Lysosomal Storage Diseases (4) · Lysosomal Storage Diseases, Nervous System (4) · Metabolic Diseases (4) · Metabolism, Inborn Errors (4) · Nervous System Diseases (4) · Nutritional and Metabolic Diseases (4)
Enzyme Replacement Therapy (1) · Genetic Therapy (1) · Glucosylceramidase (1) · Velaglucerase alfa, human (1) · arimoclomol (1) · imiglucerase (1) · taliglucerase alfa (1)
AVROBIO (1) · CANbridge (Suzhou) Bio-pharma Co., Ltd. (1) · Shire (1) · ZevraDenmark (1)
India (2) · China (1) · Egypt (1) · Tunisia (1)
Aabha Nagral, MD (1) · Bing Han, MD (1) · Milena Veselinovic, MD, PhD (1)